Nasdaq

QIAGEN Launches Therascreen BRAF Test as Companion Diagnostic to a BRAFTOVI® (encorafenib) Based Regimen in Metastatic Colorectal Cancer

QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced launch of its novel therascreen® BRAF V600E RGQ PCR Kit (therascreen BRAF V600E Kit) following U.S. Food and Drug Administration ...
Business Wire

GENECAST Launches BRAF Mutation Test Kits with the Highest Detection Sensitivity 0.0001%

Assures 100x upgraded detection sensitivity compare to ddPCR Higher the possibility of precision medicine in the 1st and 2nd stages of cancer patients SEOUL, South Korea--(BUSINESS WIRE)--GENECAST, ...
Nature

Rare BRAF mutations in melanoma patients: implications for molecular testing in clinical practice

The detection of V600E BRAF mutation in melanoma is fundamental since here BRAF inhibitors represent an effective treatment. Non-V600E BRAF mutations that may also respond are not detected by certain ...
Medscape

Most Cost-effective to Use Immunotherapy First in Melanoma

Up-front immunotherapy is the most cost-effective option for treating newly diagnosed unresectable stage III or IV melanoma with unknown BRAF mutation status, concludes a modeling analysis.
ascopubs.org

Turnaround Times in Melanoma BRAF Testing and the Impact on the Initiation of Systemic Therapy at a Single Tertiary Care Cancer Center

This study showed variations in BRAF test results in TAT. One factor affecting this timeline is the transfer time, which can be streamlined by pathology reflex testing. Delays in TAT affect the timing ...
ascopubs.org

Evolution of BRAF gene mutation testing and treatment options in BRAF mutation carriers in Canada.

BRAF exon 15 (7q34) mutation heterogeneity in metastatic and primary melanomas. This is an ASCO Meeting Abstract from the 2015 ASCO Annual Meeting I. This abstract does not include a full text ...
FierceBiotech

Ventana launches first fully automated IHC test to detect BRAF V600E mutation in a variety of cancers

"As a leader in cancer diagnostics, Ventana is committed to providing unique immunohistochemistry assays for aiding in the diagnosis and management of a variety of cancers," says Ventana President ...
EurekAlert!

KRAS and BRAF mutation screening in metastatic colorectal cancer costly in relation to benefits

Researchers report that screening for KRAS and BRAF mutations can reduce the cost of anti-EGFR treatment for metastatic colorectal cancer but with a very small reduction in overall survival according ...
Business Wire

Clarient Introduces Second Gene Mutation Test for Colorectal Cancer

ALISO VIEJO, Calif.--(BUSINESS WIRE)--Clarient, Inc. (Nasdaq:CLRT), a premier anatomic pathology and molecular testing services resource for pathologists, oncologists, and the pharmaceutical industry, ...
Yahoo

Pfizer pushing BRAF lung cancer mutation testing to grow market for Braftovi

NEW YORK (Reuters) - Pfizer is trying to increase doctor awareness of and testing for a rare lung cancer mutation to help boost use of its drug Braftovi, which the pharmaceutical maker anticipates ...
FiercePharma

Ventana launches first fully automated IHC test to detect BRAF V600E mutation in a variety of cancers

"As a leader in cancer diagnostics, Ventana is committed to providing unique immunohistochemistry assays for aiding in the diagnosis and management of a variety of cancers," says Ventana President ...